Found: 29
Select item for more details and to access through your institution.
Use of Track One Prioritized Examination for Pharmaceutical Patents.
- Published in:
- JAMA Health Forum, 2024, v. 5, n. 7, p. e241886, doi. 10.1001/jamahealthforum.2024.1886
- By:
- Publication type:
- Article
Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
- Published in:
- JAMA Internal Medicine, 2024, v. 184, n. 7, p. 810, doi. 10.1001/jamainternmed.2024.0836
- By:
- Publication type:
- Article
Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 7, p. 650, doi. 10.1001/jama.2023.13872
- By:
- Publication type:
- Article
Changes in the Number of Continuation Patents on Drugs Approved by the FDA.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 5, p. 469, doi. 10.1001/jama.2023.11525
- By:
- Publication type:
- Article
Broad Patent Claims Come Before the Supreme Court in Amgen v Sanofi.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 19, p. 1641, doi. 10.1001/jama.2023.5638
- By:
- Publication type:
- Article
Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 18, p. 1607, doi. 10.1001/jama.2023.3079
- By:
- Publication type:
- Article
Recent Patent Reform Bills and Their Implications for Prescription Drugs.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 6, p. 459, doi. 10.1001/jama.2022.24983
- By:
- Publication type:
- Article
Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 1, p. 87, doi. 10.1001/jama.2022.19691
- By:
- Publication type:
- Article
ANTIBODY PATENTS: USE OF THE WRITTEN DESCRIPTION AND ENABLEMENT REQUIREMENTS AT THE PATENT & TRADEMARK OFFICE.
- Published in:
- Berkeley Technology Law Journal, 2023, v. 38, n. 1, p. 1, doi. 10.15779/Z385Q4RN0D
- By:
- Publication type:
- Article
WHAT LITIGATORS CAN TEACH THE PATENT OFFICE ABOUT PHARMACEUTICAL PATENTS.
- Published in:
- Washington University Law Review, 2022, v. 99, n. 5, p. 1673
- By:
- Publication type:
- Article
Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA.
- Published in:
- Pharmaceutical Medicine, 2024, v. 38, n. 4, p. 303, doi. 10.1007/s40290-024-00527-w
- By:
- Publication type:
- Article
Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019.
- Published in:
- PLoS Medicine, 2023, v. 20, n. 11, p. 1, doi. 10.1371/journal.pmed.1004309
- By:
- Publication type:
- Article
Extent of Drug Patents With Terminal Disclaimers and Obviousness-Type Double Patenting Rejections.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 332, n. 10, p. 837, doi. 10.1001/jama.2024.14350
- By:
- Publication type:
- Article
Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 331, n. 11, p. 976, doi. 10.1001/jama.2024.0924
- By:
- Publication type:
- Article
Delivery Device Patents on GLP-1 Receptor Agonists.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 331, n. 9, p. 794, doi. 10.1001/jama.2024.0919
- By:
- Publication type:
- Article
Biologic Patent Thickets and Terminal Disclaimers.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 331, n. 4, p. 355, doi. 10.1001/jama.2023.25389
- By:
- Publication type:
- Article
Inequitable Conduct and Invalidation of Patents Related to Food and Drug Administration–Regulated Products.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 21, p. 2119, doi. 10.1001/jama.2023.20196
- By:
- Publication type:
- Article
Ancillary Product Patents to Extend Biologic Patent Life.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 21, p. 2117, doi. 10.1001/jama.2023.19547
- By:
- Publication type:
- Article
Free Speech Challenges to the Inflation Reduction Act.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 13, p. 1229, doi. 10.1001/jama.2023.17974
- By:
- Publication type:
- Article
Preserving Timely Generic Drug Competition with Legislation on "Skinny Labeling".
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 1, p. 22, doi. 10.1002/cpt.3075
- By:
- Publication type:
- Article
The cost of drug patent expiration date errors.
- Published in:
- Nature Biotechnology, 2024, v. 42, n. 7, p. 1024, doi. 10.1038/s41587-024-02298-w
- By:
- Publication type:
- Article
Biologic patent challenges under the America Invents Act.
- Published in:
- Nature Biotechnology, 2024, v. 42, n. 3, p. 374, doi. 10.1038/s41587-024-02156-9
- By:
- Publication type:
- Article
The prevalence of drug patent term extensions in the United States, 2000–2018.
- Published in:
- Nature Biotechnology, 2023, v. 41, n. 7, p. 903, doi. 10.1038/s41587-023-01847-z
- By:
- Publication type:
- Article
ANTIBODY CLAIMS AND THE EVOLUTION OF THE WRITTEN DESCRIPTION/ENABLEMENT REQUIREMENT.
- Published in:
- IDEA: The Intellectual Property Law Review, 2022, v. 63, n. 1, p. 84
- By:
- Publication type:
- Article
FDA REEXAMINATION: INCREASED COMMUNICATION BETWEEN THE FDA AND USPTO TO IMPROVE PATENT QUALITY.
- Published in:
- Houston Law Review, 2022, v. 60, n. 2, p. 403
- By:
- Publication type:
- Article
Why Pharmaceutical Patent Thickets Are Unique.
- Published in:
- Texas Intellectual Property Law Journal, 2024, v. 32, n. 2, p. 79
- By:
- Publication type:
- Article
Overqualified and Underrepresented: Gender Inequality in Pharmaceutical Patent Law.
- Published in:
- Brigham Young University Law Review, 2022, v. 48, n. 1, p. 137
- By:
- Publication type:
- Article
PHARMACEUTICAL PATENT TWO-STEP: THE ADVERSE ADVENT OF AMARIN V. HIKMA TYPE LITIGATION.
- Published in:
- Journal of Intellectual Property & Entertainment Law, 2022, v. 12, n. 1, p. 1
- By:
- Publication type:
- Article